CN105263499B - 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 - Google Patents

用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 Download PDF

Info

Publication number
CN105263499B
CN105263499B CN201480032428.2A CN201480032428A CN105263499B CN 105263499 B CN105263499 B CN 105263499B CN 201480032428 A CN201480032428 A CN 201480032428A CN 105263499 B CN105263499 B CN 105263499B
Authority
CN
China
Prior art keywords
days
chloro
fluoro
phenyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480032428.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263499A (zh
Inventor
B·希金斯
G·尼科尔斯
K·E·帕克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN105263499A publication Critical patent/CN105263499A/zh
Application granted granted Critical
Publication of CN105263499B publication Critical patent/CN105263499B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CN201480032428.2A 2013-06-19 2014-06-16 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 Expired - Fee Related CN105263499B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836899P 2013-06-19 2013-06-19
US61/836,899 2013-06-19
PCT/EP2014/062496 WO2014202497A1 (en) 2013-06-19 2014-06-16 Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy

Publications (2)

Publication Number Publication Date
CN105263499A CN105263499A (zh) 2016-01-20
CN105263499B true CN105263499B (zh) 2019-11-15

Family

ID=50976625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480032428.2A Expired - Fee Related CN105263499B (zh) 2013-06-19 2014-06-16 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合

Country Status (12)

Country Link
US (1) US20160129034A1 (enExample)
EP (1) EP3010508B1 (enExample)
JP (1) JP6549107B2 (enExample)
KR (1) KR20160009677A (enExample)
CN (1) CN105263499B (enExample)
BR (1) BR112015030734A2 (enExample)
CA (1) CA2912743A1 (enExample)
ES (1) ES2747073T3 (enExample)
MX (1) MX2015017124A (enExample)
PL (1) PL3010508T3 (enExample)
RU (1) RU2015152175A (enExample)
WO (1) WO2014202497A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021033144A1 (en) * 2019-08-20 2021-02-25 Intas Pharmaceuticals Ltd. Oral suspension of capecitabine
CN113698435B (zh) * 2021-08-25 2023-09-29 中国人民解放军空军军医大学 一类含有p53-MDM2抑制剂的四价铂配合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531321A (ja) * 2006-03-22 2009-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202102855RA (en) * 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531321A (ja) * 2006-03-22 2009-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
卡培他滨联合奥沙利铂一线治疗转移性结、直肠癌疗效分析;赵文英等;《中国医药导刊》;20121231;第12卷(第2期);254-255 *
赵文英等.卡培他滨联合奥沙利铂一线治疗转移性结、直肠癌疗效分析.《中国医药导刊》.2010,第12卷(第1期),254-255. *

Also Published As

Publication number Publication date
JP2016521760A (ja) 2016-07-25
KR20160009677A (ko) 2016-01-26
RU2015152175A3 (enExample) 2018-04-02
EP3010508A1 (en) 2016-04-27
MX2015017124A (es) 2016-03-07
EP3010508B1 (en) 2019-07-24
BR112015030734A2 (pt) 2017-07-25
RU2015152175A (ru) 2017-07-24
US20160129034A1 (en) 2016-05-12
JP6549107B2 (ja) 2019-07-24
WO2014202497A1 (en) 2014-12-24
CA2912743A1 (en) 2014-12-24
ES2747073T3 (es) 2020-03-10
HK1213475A1 (zh) 2016-07-08
CN105263499A (zh) 2016-01-20
PL3010508T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP5765634B2 (ja) 低酸素活性化型プロドラッグを用いるがんの処置
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
WO2006080327A1 (ja) α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
ES2848706T3 (es) Terapia de combinación contra el cáncer usando un compuesto azabicíclico
EP2817011B1 (en) Treatment of cancer
RS58608B1 (sr) Kombinovana terapija sa antitumorskim antibiotikom
JP2012515184A (ja) 大腸がんの治療方法
US11524009B2 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
RS64778B1 (sr) Lečenje raka
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
EP2262493B1 (en) Methods of treatment employing prolonged continuous infusion of belinostat
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
HK1213475B (zh) 用於癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
EP3010513B1 (en) Combination of ro5503781 and capecitabine for cancer therapy
WO2013137433A1 (ja) ３剤を組み合わせた新規な抗腫瘍剤
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
TH1901007379A (th) ตัวยับยั้ง kras g12c และวิธีการใช้สิ่งดังกล่าว
HK1204956B (en) Treatment of cancer
HK1152247B (en) Methods of treatment employing prolonged continuous infusion of belinostat
TW200940061A (en) Combination comprising bosentan for treating ovarian cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213475

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191115

Termination date: 20210616

CF01 Termination of patent right due to non-payment of annual fee